Carboplatin and Chlorambucil for Advanced Ovarian Cancer
Author Information
Author(s): M. Harding, R. Kennedy, L. Mill, A. MacLean, I. Duncan, J. Kennedy, M. Soukop, S.B. Kaye
Primary Institution: University of Glasgow
Hypothesis
Can carboplatin and chlorambucil be effectively combined for treating advanced ovarian cancer?
Conclusion
The combination of carboplatin and chlorambucil shows a satisfactory degree of efficacy with less toxicity than cisplatin-based regimens.
Supporting Evidence
- Five complete and 16 partial remissions were observed in 37 evaluable patients.
- The overall response rate was 57%.
- The median survival of all patients was 15 months.
- Myelosuppression was the major toxicity observed.
Takeaway
Doctors tested a new medicine mix to help women with a serious type of cancer, and it worked pretty well without making them too sick.
Methodology
Patients received carboplatin and chlorambucil in various doses, and their tumor responses were assessed after treatment.
Limitations
The study had a small sample size and was not randomized.
Participant Demographics
Patients aged 24-71 years, median age 59, with advanced epithelial ovarian cancer.
Want to read the original?
Access the complete publication on the publisher's website